Efficacy and Safety of Thymoquinone on Suppression of Tumor Growth in N-butyl-N-(4-hydroxybutyl)-Nitrosamine -Induced Bladder Cancer in Rats

Q3 Pharmacology, Toxicology and Pharmaceutics
Karmand Salih Hamaamin Qadir, Bushra Hassan Marouf
{"title":"Efficacy and Safety of Thymoquinone on Suppression of Tumor Growth in N-butyl-N-(4-hydroxybutyl)-Nitrosamine -Induced Bladder Cancer in Rats","authors":"Karmand Salih Hamaamin Qadir, Bushra Hassan Marouf","doi":"10.31351/vol32iss2pp150-161","DOIUrl":null,"url":null,"abstract":"Bladder cancer is one of the most common genitourinary malignancies worldwide, the therapeutic approaches for suppression of urothelial tumor and progression toward distant metastasis are not convincing. The present study was conducted to explore the curative effect and safety of THQ in N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced bladder cancer in rat.
 Twenty-two male Wister albino rats were allocated into three group G1; served as control (n=6) received only the vehicle. G2: carcinogen group (n=6); animals had 0.05% BBN in drinking water for nine weeks. G3: Treatment group (n=10); THQ was administered at a dose of 50mg/Kg/day orally one week prior to the last exposure of BBN and continued till week 20. The bladder wall of all the animals was examined macroscopically for assessment of the number and the surface area of the lesions using Image J software program. Histopathological evaluation was also done for abnormal morphological alterations. Serum was analyzed for measurement of total oxidant status (TOS) and nuclear factor kappa- κB (NF-κB), transforming growth factor beta-1 (TGF-β1) as well as vascular endothelial growth factor (VEGF). Safety of THQ in respect of hematological, liver and renal function were also investigated. Bladder lesions in the THQ-treated group was reduced versus the carcinogen group. Histopathological findings in THQ-treated group demonstrated a significant improvement in the abnormal morphological growth in bladder, the TOS, NF-kβ, TGF-β, VEGF were mitigated non-significantly in the treatment group. The safety profile of THQ showed no significant deleterious effect on hematological, liver and renal function parameters with no signs of toxicity. THQ inhibited the development of neoplastic, preneoplastic transformations and it suppressed premalignant and malignant lesion formation in a rat model of bladder cancer. This might be due to antioxidant and anti-inflammatory properties of THQ. These data suggested that THQ may be effective and safe in ameliorating urinary bladder carcinogenesis.","PeriodicalId":14600,"journal":{"name":"Iraqi Journal of Pharmaceutical Sciences","volume":"69 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iraqi Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31351/vol32iss2pp150-161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Bladder cancer is one of the most common genitourinary malignancies worldwide, the therapeutic approaches for suppression of urothelial tumor and progression toward distant metastasis are not convincing. The present study was conducted to explore the curative effect and safety of THQ in N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced bladder cancer in rat. Twenty-two male Wister albino rats were allocated into three group G1; served as control (n=6) received only the vehicle. G2: carcinogen group (n=6); animals had 0.05% BBN in drinking water for nine weeks. G3: Treatment group (n=10); THQ was administered at a dose of 50mg/Kg/day orally one week prior to the last exposure of BBN and continued till week 20. The bladder wall of all the animals was examined macroscopically for assessment of the number and the surface area of the lesions using Image J software program. Histopathological evaluation was also done for abnormal morphological alterations. Serum was analyzed for measurement of total oxidant status (TOS) and nuclear factor kappa- κB (NF-κB), transforming growth factor beta-1 (TGF-β1) as well as vascular endothelial growth factor (VEGF). Safety of THQ in respect of hematological, liver and renal function were also investigated. Bladder lesions in the THQ-treated group was reduced versus the carcinogen group. Histopathological findings in THQ-treated group demonstrated a significant improvement in the abnormal morphological growth in bladder, the TOS, NF-kβ, TGF-β, VEGF were mitigated non-significantly in the treatment group. The safety profile of THQ showed no significant deleterious effect on hematological, liver and renal function parameters with no signs of toxicity. THQ inhibited the development of neoplastic, preneoplastic transformations and it suppressed premalignant and malignant lesion formation in a rat model of bladder cancer. This might be due to antioxidant and anti-inflammatory properties of THQ. These data suggested that THQ may be effective and safe in ameliorating urinary bladder carcinogenesis.
百里醌抑制n -丁基- n -(4-羟基丁基)-亚硝胺诱导膀胱癌大鼠肿瘤生长的有效性和安全性
膀胱癌是世界范围内最常见的泌尿生殖系统恶性肿瘤之一,其抑制尿路上皮肿瘤和向远处转移的治疗方法尚不令人信服。本研究旨在探讨THQ对n -丁基- n -(4-羟基丁基)亚硝胺(BBN)诱导大鼠膀胱癌的疗效和安全性。 雄性白化Wister大鼠22只,分为G1组;作为对照组(n=6),只接受载具。G2:致癌物组(n=6);动物连续9周饮用含有0.05% BBN的水。G3:治疗组,n=10;在最后一次接触BBN前一周,以50mg/Kg/天的剂量口服THQ,并持续到第20周。采用Image J软件程序对所有动物膀胱壁进行宏观检查,以评估病变的数量和表面积。组织病理学评估异常形态学改变。测定血清总氧化状态(TOS)、核因子κB (NF-κB)、转化生长因子β -1 (TGF-β1)、血管内皮生长因子(VEGF)。此外,还对THQ在血液学、肝肾功能方面的安全性进行了研究。与致癌物组相比,thq治疗组膀胱病变减少。四氢棉素组膀胱异常形态生长明显改善,TOS、NF-kβ、TGF-β、VEGF均无明显减轻。四氢大麻素的安全性对血液学、肝肾功能指标无明显不良影响,无毒性迹象。在大鼠膀胱癌模型中,THQ抑制肿瘤、瘤前转化的发展,抑制癌前病变和恶性病变的形成。这可能是由于THQ的抗氧化和抗炎特性。这些数据表明THQ在改善膀胱癌变方面可能是有效和安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Iraqi Journal of Pharmaceutical Sciences
Iraqi Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.40
自引率
0.00%
发文量
37
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信